Imatinib mesylate-induced psoriasiform drug reaction: A case of dose-dependent cutaneous toxicity
نویسندگان
چکیده
منابع مشابه
Imatinib mesylate-induced lichenoid drug eruption.
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...
متن کاملImatinib mesylate: A designer drug.
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positiv...
متن کاملLichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
500 Ann Dermatol Received October 19, 2012, Revised December 1, 2012, Accepted for publication December 5, 2012 Corresponding author: Dong-Youn Lee, Department of Dermatology, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: 82-2-3410-3543, Fax: 82-2-3410-3869, E-mail: dylee@ skku.edu This is an Open Access article distributed under the terms of the Creative Commons A...
متن کاملCutaneous adverse effects of imatinib mesylate
A 52-year -old female patient was found to have elevated white blood cell count (WBC) on routine physical examination. Her WBC count was 67.260/ uL, hemoglobin was 8.3 gm/dL, hematocrit was 26.1% and platelet count was 133,000/uL. Bone marrow reveled myeloid hyperplasia and the Philadelphia chromosome was positive. Patient was diagnosed as chronic myeloid leukemia (CML) and imatinib mesylate tr...
متن کاملPityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug erupti...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Drugs in Dermatology
سال: 2021
ISSN: 2455-3972
DOI: 10.4103/ijdd.ijdd_25_20